fbpx

UNIQUE PLATFORM FOR THE DEVELOPMENT OF ANTIVIRAL INNOVATIVE DRUGS

UNIQUE PLATFORM FOR THE DEVELOPMENT OF ANTIVIRAL INNOVATIVE DRUGS

ChemDiv, Inc has created a unique platform for the development of innovative drugs against
the new coronavirus infection.

background
ChemDiv, Inc has created a unique platform
for the development of innovative drugs
against the new coronavirus infection.
The platform includes specially designed libraries of potentially active antiviral (SARS-CoV-2) small molecules, sets of methods, including virtual screening and test systems that allow detecting the activity of invitro compounds in a high-performance format with subsequent in vivo validation of the lead compounds. The platform ensures the development of lead compounds and preclinical candidates from scratch in just a few months. The advantages of the created service are its completeness and speed of work.

The platform combines Libraries of more than 120,000 unique Potential Antiviral Molecules that target various cellular proteins. Libraries cover highly-concerned coronavirus area as well as HIV, HBV, Influenza. More than 50 antiviral targets (Antiviral Annotated Library 22,775 compounds, CORONAVIRUS Library 21,145 compounds, PLpro Library 6,442 compounds, 3CLpro Library 4,871 compounds, ACE2 Library 3,117 compounds, Antiviral Library 87,043 compounds and others).

Testing systems provides CPE testing with SARS-CoV-2 virus, Protease tests (3CL and PLpro), Polymerase tests (RdRp), Spike Study (ACE2-S1), Investigation of the antiviral activity of a future hamster candidate, Pharmacokinetic studies, Medical and chemical optimization services.

ChemDiv has been performing research and development in the field of medical and pharmaceutical chemistry for over 30 years. A world-class team of specialists and scientists ensures the company’s global leadership in the industry. ChemDiv invites Pharmaceutical companies and research laboratories to develop innovative drugs against COVID-19.
> Antiviral Annotated Library
22,775 compounds
Description, Slides
Structures, SDF
> PLpro Library
6,442 compounds
Description, Slides
Structures, SDF
> 3CLpro Library
4,871 compounds
Description, Slides
Structures, SDF
> ACE2 Library
222; 3,117 compounds
Description, Slides
Structures, SDF
> Anti-HIV1 Library
21,000 compounds
Description, Slides
Structures, SDF
> Antiviral Library
87,043 compounds
Description. Slides
Structures, SDF
> Antiviral HBV
11,000 compounds
Description, Slides
Structures, SDF
> CORONAVIRUS Library
21,145 compounds
Description, Slides
Structures, SDF
SEARCH ONLINE AND PURCHASE IN OUR 1.6 MILLION STOCK
background background
OUR MOST POPULAR SCREENING LIBRARIES
In addition to our newest compound collections, please take a look at our most popular libraries:
Covalent inhibitors Library (12,000 compounds) Structures
Nucleoside Mimetics Library (2,600 Compounds) Structures
SH2 Library (12,000 compounds) Structures
SH2 PTB Focused Library (7,000 compounds) Structures
Lipid Metabolism Library (9,000 compounds) Structures
Chelators targeting matrix metalloproteinases library (9,300 compounds) Structures
Histone Deacetylases (HDAC) Targeted Library Selection (9,500 compounds) Structures
Protein-Protein Interaction Library (222,500 compounds) Structures
Library of Small Molecule Inhibitors of beta-Catenin Signaling (8,000 compounds) Structures
MDM2-p53 interaction inhibitors Library (23,000 compounds) Structures
OUR STOCK AVAILABLE COMPOUND COLLECTIONS
> Structures of ChemDiv’s Stock Compound Collection Click Here
> Building Blocks collection, more than 74,329 unique building blocks Click Here
> Complete List of Our Targeted and Focused Compound Libraries Click Here
> Complete List of Our Active Reference Sets Click Here
> Complete List of Our Diversity libraries Click Here
We will be happy to hear your requests, comments or questions at lt@chemdiv.com or sb@chemdiv.com or chemdiv@chemdiv.com
August 3, 2020 / Blog
X
Send a message
Request a call

    * Required fields

    By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.

      * Required fields

      By submitting this form you confirm that you have read and accepted our privacy policy. Your data will be used exclusively for this purpose.

      X